Publicacions en què col·labora amb Enrique Álvarez (10)

2019

  1. Patient characteristics driving clinical utility in psychiatric pharmacogenetics: a reanalysis from the AB-GEN multicentric trial

    Journal of Neural Transmission, Vol. 126, Núm. 1, pp. 95-99

2017

  1. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial

    BMC Psychiatry, Vol. 17, Núm. 1

2011

  1. Clinical meaningful outcomes in schizophrenia: Remission and recovery

    Revista de Psiquiatria y Salud Mental, Vol. 4, Núm. 1, pp. 53-65

2009

  1. Recovery from schizophrenia: Results from a 1-year follow-up observational study of patients in symptomatic remission

    Schizophrenia Research, Vol. 115, Núm. 1, pp. 58-66

  2. Remission in schizophrenia: Results from a 1-year follow-up observational study

    Schizophrenia Research, Vol. 108, Núm. 1-3, pp. 214-222

2005

  1. Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951

  2. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting

    Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486

2003

  1. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481

  2. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

    European Neuropsychopharmacology, Vol. 13, Núm. 1, pp. 39-48

2002

  1. Treatment of severely psychotic inpatients with schizophrenia: Olanzapine versus other antipsychotic drugs

    International Clinical Psychopharmacology, Vol. 17, Núm. 6, pp. 287-295